ReviewInternational journal of molecular sciences2021
Antibiotic-Related Changes in Microbiome: The Hidden Villain behind Colorectal Carcinoma Immunotherapy Failure.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 32 citations in OpenAlex.
- Modulating the gut microbiota to enhance immune checkpoint inhibitor efficacy in colorectal cancer: mechanisms, therapeutic strategies, and clinical perspectives.Gut microbes · 2026Review
- Re-arming checkpoint blockade in MSS colorectal cancer: A precision-microbiome playbook from mechanisms to clinic.Turkish journal of surgery · 2026Article
- Association Between Antibiotic Therapy and Treatment Effectiveness in Patients With Renal Cell Carcinoma Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors.JCO oncology practice · 2026Article
- Across the Social Network of the Gut: Bacterial, Fungal, and Viral Determinants of Checkpoint Inhibitor Efficacy and Toxicity.International journal of molecular sciences · 2026Review
- Review
- Review
- Therapeutic potential of microbiome modulation in reproductive cancers.Medical oncology (Northwood, London, England) · 2025Review
- Association Between Antibiotic and Outcomes of Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer: A Multicenter Retrospective Study of 132 Patients.Thoracic cancer · 2025Article
- Microbiota-mediated modulation of radiosensitivity: mechanisms and therapeutic prospects of oral and gut microbiota, metabolites, and probiotics.Frontiers in microbiology · 2025Review
- New strategies in the diagnosis and treatment of immune-checkpoint inhibitor-mediated colitis.World journal of clinical cases · 2024Review
- Gut microbiota as a biomarker and modulator of anti-tumor immunotherapy outcomes.Frontiers in immunology · 2024Review
- The role of intestinal flora on tumorigenesis, progression, and the efficacy of PD-1/PD-L1 antibodies in colorectal cancer.Cancer biology & medicine · 2023Review
- Advancing translational research for colorectal immuno-oncology.British journal of cancer · 2023Review
- Gut Microbiome Composition and Its Metabolites Are a Key Regulating Factor for Malignant Transformation, Metastasis and Antitumor Immunity.International journal of molecular sciences · 2023Review
- The Gut Microbiome, Microsatellite Status and the Response to Immunotherapy in Colorectal Cancer.International journal of molecular sciences · 2023Review
- A New Treatment Landscape for RCC: Association of the Human Microbiome with Improved Outcomes in RCC.Cancers · 2023Review
- Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy.Frontiers of medicine · 2022Review
- The Role of Gut Microbiota in Gastrointestinal Tract Cancers.Archivum immunologiae et therapiae experimentalis · 2022Review
- The role of gut microbiome in immune modulation in metastatic renal cell carcinoma.Therapeutic advances in medical oncology · 2022Review
- The difference of human gut microbiome in colorectal cancer with and without metastases.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
The interplay between drugs and microbiota is critical for successful treatment. An accumulating amount of evidence has identified the significant impact of intestinal microbiota composition on cancer treatment response, particularly immunotherapy. The possible molecular pathways of the interaction between immune checkpoint inhibitors (ICIs) and the microbiome can be used to reverse immunotherapy tolerance in cancer by using various kinds of interventions on the intestinal bacteria. This paper aimed to review the data available on how the antibiotic-related changes in human microbiota during colorectal cancer (CRC) treatment can affect and determine ICI treatment outcomes. We also covered the data that support the potential intimate mechanisms of both local and systemic immune responses induced by changes in the intestinal microbiota. However, further better-powered studies are needed to thoroughly assess the clinical significance of antibiotic-induced alteration of the gut microbiota and its impact on CRC treatment by direct observations of patients receiving antibiotic treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.